Eligible patients are UC patients diagnosed with CML-Ph+ or CD117 positive GIST whose household incomes are less than 100,000 baht (US$3,225) per year. This evidence concerns the gene KIT and chronic myelogenous leukemia, BCR-ABL1 positive.